Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL322908

CCOc1ccc(F)cc1.N

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 1/20 0.70
TDP1 Q9NUW8 2/20 0.62
CYP1A2 P05177 1/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C19 P33261 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
TSHR P16473 1/20 0.56
MAOB P27338 1/20 0.53
LTA4H P09960 2/20 0.52
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 2/20 0.49
PLK1 P53350 1/20 0.48
PARP10 Q53GL7 1/20 0.47
RELA Q04206 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1547683 0.97 NQO1 (0.74) NQO1TDP1CYP1A2CYP2D6CYP2C19
SCHEMBL22874669 0.91 LTA4H (0.65) NQO1TDP1CYP1A2CYP2D6CYP2C19
SCHEMBL27947692 0.87 NQO1 (0.58) NQO1TDP1CYP1A2CYP2D6CYP2C19
SCHEMBL8375667 0.87 NQO1 (0.58) NQO1TDP1CYP1A2CYP2D6CYP2C19
SCHEMBL22874653 0.85 MAOB (0.67) NQO1TDP1CYP1A2CYP2D6CYP2C19
1,4-Diethoxybenzene SCHEMBL28186701 0.84 NQO1 (1.00) NQO1TDP1TSHRLTA4HALDH1A1
1,4-Diethoxybenzene SCHEMBL124015 0.84 NQO1 (1.00) NQO1TDP1TSHRLTA4HALDH1A1
Carbamic Acid SCHEMBL11793902 0.83 PARP10 (0.61) NQO1TDP1CYP1A2CYP2D6CYP2C19
SCHEMBL11042318 0.82 KMT2A (0.67) NQO1L3MBTL1TSHRMAOBKMT2A
SCHEMBL20767219 0.82 LMNA (0.63) NQO1TDP1CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 US disclosed
US-9452164-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2016-09-27 US disclosed
CN-103080111-B Imidazopyridine derivatives, its preparation method and therapeutical uses thereof 赛诺菲 2016-06-15 CN disclosed
EP-2800566-B1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI SA (FR) 2015-10-28 EP disclosed
EP-2590976-B1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-09-16 EP disclosed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 US disclosed
EP-2800566-A1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI (FR) 2014-11-12 EP disclosed
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-28 US disclosed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 US disclosed
WO-2013102860-A1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI (FR) 2013-07-11 WO disclosed
EP-2590976-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 EP disclosed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
CN-103080111-A Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI SA 2013-05-01 CN disclosed
WO-2012004732-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH NQO1 13/4885TDP1 1985/4885CYP1A2 86/4885
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives CCNY, UTS2R, WNK2 NQO1 166/4885TDP1 2670/4885CYP1A2 2043/4885
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH NQO1 13/4885TDP1 1985/4885CYP1A2 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.